Groq Health reached settlement territory after a federal judge found enough factual disputes about AI, health apps, domain searches, and affiliation confusion to keep the trademark case moving toward trial.
A Settlement After The Case Survived Summary Judgment
On May 18, 2026, Judge Mary Kay Vyskocil received a letter saying the parties in Groq, Inc. v. Groq Health, Inc. and Florence D. Comite, M.D. had reached a settlement in principle. The US District Court for the Southern District of New York then dismissed the action without costs, while allowing either side to restore the case by June 18, 2026 if the settlement is not put into writing.
If no restoration application is filed by that date, the dismissal becomes with prejudice. The public record leaves the settlement terms undisclosed. What it does show is a case that had already become expensive and risky.
The lawsuit was filed on September 20, 2023 under case number 1:23-cv-08325-MKV. Groq, Inc. asserted trademark infringement, false designation of origin, New York common-law infringement, business reputation and dilution, and unfair-competition claims. Groq Health and Dr. Comite tried to end the case on summary judgment, arguing that the record could not support a finding of likely confusion.
That effort failed. In the March 16 summary judgment order, the court found factual disputes across nearly all of the Polaroid likelihood-of-confusion factors. The May 18 dismissal order ended the litigation posture. The March 16 order explains why the name dispute had settlement value.
Why The Court Saw More Than Two Different Products
Groq Health’s strongest argument was simple. Groq, Inc. made AI microchips, hardware, cloud services, and related technology. Groq Health offered a health mobile app that used biomarkers, sleep data, nutrition, exercise, personal and family health history, blood draws, performance assessments, and wearable-health data to build a user profile.
Different products. Different customers. Different markets.
The court treated that difference as insufficient. Trademark confusion under the Lanham Act can include confusion about affiliation, connection, or association. A consumer could see Groq Health as connected to Groq’s chips, cloud, API, or AI technology even if the app came from a separate company.
That is why the product-boundary evidence mattered. Groq submitted evidence that it offered software, cloud platforms, APIs, a chatbot, consulting services, and healthcare-related technology interests. Groq Health, meanwhile, had AI plans of its own. Dr. Comite testified that AI integration into the app was critical to the business plan and would be widely promoted.
The shared wording also mattered. The court found that “Groq” was the dominant word in both names and declined to rule that adding “Health” eliminated confusion as a matter of law. A descriptive modifier can help while still leaving risk when the distinctive term stays intact.
Groq also offered a mistaken LinkedIn tag and survey evidence showing slightly more than 20 percent confusion in each survey. The court treated the weight of that evidence as a trial issue. For a founder, that distinction changes the risk calculation. A case can become expensive long before anyone proves infringement, especially when the record contains enough consumer-perception evidence to keep the dispute alive. That is why how trademark infringement and dilution claims differ matters less as an abstract legal lesson than as a way to understand what evidence keeps a name dispute moving.
AI Makes Product Boundaries Harder To Police
Groq, Inc. was founded in 2016 by Jonathan Ross and a co-founder. The company designs Language Processing Units, specialized chips for AI inference, and the court record described evidence of cloud platforms, APIs, a chatbot, and consulting services layered around that hardware business.
Groq Health started from a different commercial idea. Its app was built around personalized health data, including biomarkers, health history, and wearable inputs. On paper, that sounds far from AI infrastructure. In the market, the distance becomes narrower once the app plans to promote AI features.
That narrowing is common in technology branding. An AI chip company can become an infrastructure brand. APIs move into many industries. Healthcare companies market AI as part of diagnosis, prediction, coaching, or personalization. When a health app uses a near-identical name to an AI infrastructure company, the public may ask whether one powers, sponsors, endorses, or supports the other. Trademark clearance has to account for that commercial story alongside the category label on a filing.
The Groq and Grok naming field adds useful secondary context. Phonetic similarity and stylized tech spelling can create risk even when a founder thinks a letter change is enough. The court left infringement undecided and held that the evidence supported sending confusion questions toward trial.
The warning for founders is direct. The name has to survive the company’s likely product path as well as its first description. If your app, API, AI feature, or platform may expand into a related market, the clearance review has to test that future use. Software and app names can function as trademarks, and the market will read them in context.
What A Better Clearance Review Would Have Tested
The court record describes a naming path that should make founders uncomfortable. Dr. Comite testified that she came up with Groq Health over Labor Day weekend in September 2020. She wanted “Grok” with a K, but moved away from that spelling after a search revealed a medical or dental company named Grok Health and the domain was unavailable.
GroqHealth.com and related domains were available. That solved a web-address problem while leaving the trademark problem alive. Domain availability says a string can be purchased. It says nothing about whether the name can be used in commerce without drawing a conflict.
A December 2020 trademark clearance search disclosed Groq, Inc. to Dr. Comite. Groq later sent a cease-and-desist letter in June 2022. The lawsuit followed in September 2023. By the time the case settled in principle in May 2026, the naming issue had consumed years.
A better review would have tested exact matches, phonetic equivalents, and spelling variants. The shift from Grok to Groq is exactly the sort of K/Q substitution that tech naming often uses, and trademark law looks past spelling. Sound, meaning, appearance, marketplace context, and related services all matter.
The review also should have looked beyond registered marks. Groq had federal registrations, GROQCLOUD rights, multiple GROQ-formative applications, and public technology expansion evidence. That kind of portfolio points to a brand family broader than a one-off mark. A founder choosing a related name has to ask whether customers, developers, investors, journalists, or app users will assume a connection.
When I review a proposed name, I want to know how it will sound after the company expands as well as how it looks on day one. If the business plan depends on AI features, healthcare use cases, APIs, data infrastructure, or platform partnerships, the search has to test those claims before marketing trains the market. A deeper trademark search before launch gives you those answers while the name is still flexible.
The Name You Choose Today Has To Survive Tomorrow’s Product
The Groq Health record shows a trademark clearance search, a cease-and-desist letter, and years of litigation before a settlement in principle closed the file. The conflict was visible early, but the cost of dealing with it grew as the product, company, and name became more public. The least expensive time to fix a naming conflict is before launch, fundraising, press coverage, app-store promotion, and customer adoption lock the brand into place.
I help businesses evaluate names before those commitments harden. That means clearance searches, federal registration strategy, conflict analysis, and practical options when a name carries risk. Sometimes the right move is a stronger name. Sometimes it is a modified filing strategy. Sometimes it is moving forward with a clear understanding of what would need to be defended.
If you are choosing a business name, software product name, AI application name, or healthcare technology brand, treat domain availability as the start of clearance and keep going until the trademark risk has been tested. Contact my office before the name goes live. A careful review at the front end costs far less than litigating after the market already knows you by a name you may have to change.
